NCT00760032

Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients

Association of Serum Levels of Lipopolysaccharide Binding Protein (LBP) With the Evolution of Pro- and Anti-inflammatory Cytokines, and the Development of Severe Infectious Events in Cirrhotic Patients

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Florencia Vargas-Vorackova · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether plasma levels of lipopolysaccharide binding protein (LBP) are correlated with PBMN pro- and anti-inflammatory cytokine secretion, as well as with the development of severe infectious events in cirrhotic patients with ascites. As a secondary purpose, the study will evaluate the effect of a prophylactic administration of ciprofloxacin on LBP, cytokines and infections in the same patients.

Conditions

• Cirrhosis
• Ascites
• Infections

Interventions

Type	Name	Description
DRUG	Ciprofloxacin	Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
DRUG	Placebo	Placebo capsules, one capsule per day during four weeks.

Timeline

• First posted: 2008-09-25
• Last updated: 2012-12-05

Locations

1 site across 1 country: Mexico